Skip to main content

Intra-Cellular Therapies, Inc.

ITCIDelisted Apr 2, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001567514

Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Intra-Cellular Therapies, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Intra-Cellular Therapies, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Intra-Cellular Therapies, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Riggs Rory BDirector0Apr 2, 20250
Marcus Joel SDirector0IndirectApr 2, 20250
Van Nostrand Robert LDirector0Apr 2, 20250
Halstead MichaelPresident0Apr 2, 20250
Mates SharonChairman and CEO0IndirectApr 2, 20250
Neumann MarkEVP, Chief Commercial Officer0Apr 2, 20250
Narula SanjeevExecutive Vice President & CFO–Apr 2, 20250
Durgam Suresh K.EVP, Chief Medical Officer0Apr 2, 20250
Salas Eduardo ReneDirector0Apr 2, 20250
Hineline Lawrence J.SVP of Finance, CFO0Mar 11, 20240
Rawlins MichaelDirector–Jun 13, 20220
Lerner Richard ADirector96,663IndirectOct 4, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 16, 2023 (view filing)Jun 142 daysHineline Lawrence J.SVP of Finance CFOSSale−81.9K$63.97−$5.24M−100.0%0 after3 lots10b5-1
Jul 20, 2023 (view filing)Jul 173 daysLateDurgam Suresh K.EVP, Chief Medical OfficerSSale−1.84K$65.00−$119.7K−8.0%21.3K after10b5-1
Aug 9, 2023 (view filing)Aug 72 daysNeumann MarkEVP, Chief Commercial OfficerSSale−55.3K$58.79−$3.25M−54.9%45.3K after
Sep 19, 2023 (view filing)Sep 18-191 dayMates SharonChairman, President & CEOSSale−100.0K$53.94−$5.39M−8.7%1.05M after3 lots10b5-1
Nov 8, 2023 (view filing)Nov 62 daysNeumann MarkEVP, Chief Commercial OfficerSSale−42.4K$55.63−$2.36M−58.8%29.7K after2 lots
Nov 14, 2023 (view filing)Nov 131 dayHalstead MichaelEVP and General CounselSSale−50.0K$53.90−$2.69M−100.0%0 after2 lots10b5-1
Dec 15, 2023 (view filing)Dec 132 daysDurgam Suresh K.EVP, Chief Medical OfficerSSale−21.3K$65.00−$1.38M−100.0%0 after10b5-1
Jan 4, 2024 (view filing)Jan 22 daysDurgam Suresh K.EVP, Chief Medical OfficerSSale−62.3K$70.60−$4.40M−100.0%0 after3 lots10b5-1
Jan 12, 2024 (view filing)Jan 111 dayHalstead MichaelEVP and General CounselSSale−50.0K$66.83−$3.34M−100.0%0 after3 lots10b5-1
Jan 18, 2024 (view filing)Jan 16-182 daysMates SharonChairman, President & CEOSSale−191.4K$66.27−$12.7M−15.4%1.05M after7 lots10b5-1
Feb 5, 2024 (view filing)Feb 23 daysDurgam Suresh K.EVP, Chief Medical OfficerSSale−6.17K$67.19−$414.4K−52.0%5.69K after2 lots10b5-1
Feb 5, 2024 (view filing)Feb 23 daysHineline Lawrence J.SVP of Finance, CFOSSale−11.2K$66.62−$745.0K−100.0%0 after2 lots10b5-1
Feb 5, 2024 (view filing)Feb 23 daysNeumann MarkEVP, Chief Commercial OfficerSSale−11.9K$67.15−$796.4K−28.5%29.7K after2 lots10b5-1
Feb 5, 2024 (view filing)Feb 23 daysMates SharonChairman, President & CEOSSale−33.9K$67.07−$2.27M−3.1%1.05M after2 lots10b5-1
Feb 5, 2024 (view filing)Feb 23 daysHalstead MichaelEVP and General CounselSSale−11.9K$66.42−$787.7K−100.0%0 after2 lots10b5-1
Feb 27, 2024 (view filing)Feb 261 dayMarcus Joel SDirectorSSale−26.3K$68.68−$1.81M−39.9%39.7K after3 lots
Feb 27, 2024 (view filing)Feb 261 dayNeumann MarkEVP, Chief Commercial OfficerSSale−7.91K$70.13−$554.5K−21.0%29.7K after4 lots10b5-1
Feb 27, 2024 (view filing)Feb 261 dayDurgam Suresh K.EVP, Chief Medical OfficerSSale−4.11K$70.17−$288.5K−30.2%9.49K after3 lots10b5-1
Feb 27, 2024 (view filing)Feb 261 dayMates SharonChairman, President & CEOSSale−22.6K$69.79−$1.58M−2.1%1.05M after3 lots10b5-1
Feb 27, 2024 (view filing)Feb 261 dayHineline Lawrence J.SVP of Finance, CFOSSale−13.3K$69.43−$926.0K−100.0%0 after5 lots10b5-1
Feb 27, 2024 (view filing)Feb 261 dayHalstead MichaelEVP and General CounselSSale−7.91K$69.53−$549.8K−100.0%0 after3 lots10b5-1
Feb 28, 2024 (view filing)Feb 271 dayVan Nostrand Robert LDirectorSSale−20.0K$72.93−$1.46M−67.5%9.61K after2 lots
Mar 11, 2024 (view filing)Mar 7-114 daysDurgam Suresh K.EVP, Chief Medical OfficerSSale−10.2K$66.21−$672.8K−33.9%19.8K after5 lots10b5-1
Mar 11, 2024 (view filing)Mar 7-114 daysNeumann MarkEVP, Chief Commercial OfficerSSale−20.5K$66.23−$1.36M−40.8%29.7K after5 lots10b5-1
Mar 11, 2024 (view filing)Mar 7-114 daysHalstead MichaelEVP and General CounselSSale−20.5K$66.09−$1.35M−100.0%0 after4 lots10b5-1
Mar 11, 2024 (view filing)Mar 7-114 daysHineline Lawrence J.SVP of Finance, CFOSSale−23.3K$66.32−$1.54M−100.0%0 after7 lots10b5-1
Mar 11, 2024 (view filing)Mar 7-114 daysMates SharonChairman, President & CEOSSale−61.3K$66.07−$4.05M−5.5%1.05M after6 lots10b5-1
Jun 21, 2024 (view filing)Jun 183 daysVan Nostrand Robert LDirectorSSale−20.0K$75.91−$1.52M−67.4%9.69K after2 lots10b5-1
Jun 25, 2024 (view filing)Jun 241 dayRiggs Rory BDirectorSSale−4.46K$75.57−$337.2K−3.7%116.6K after
Aug 20, 2024 (view filing)Aug 164 daysNeumann MarkEVP, Chief Commercial OfficerSSale−18.7K$75.08−$1.41M−38.7%29.7K after
Aug 23, 2024 (view filing)Aug 21-232 daysMates SharonChairman and CEOSSale−121.1K$75.05−$9.09M−10.2%1.07M after7 lots10b5-1
Aug 28, 2024 (view filing)Aug 26-282 daysMates SharonChairman and CEOSSale−95.9K$73.54−$7.05M−8.2%1.07M after5 lots10b5-1
Aug 30, 2024 (view filing)Aug 29-301 dayMates SharonChairman and CEOSSale−70.0K$72.70−$5.09M−6.1%1.07M after4 lots10b5-1
Nov 14, 2024 (view filing)Nov 12-132 daysHalstead MichaelPresidentSSale−41.6K$88.79−$3.69M−100.0%0 after5 lots10b5-1
Dec 6, 2024 (view filing)Dec 4-52 daysMates SharonChairman and CEOSSale−102.7K$84.93−$8.72M−8.8%1.07M after4 lots10b5-1